Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
McKesson
Farmers Insurance
Teva
Cantor Fitzgerald
Moodys
Medtronic
Baxter
Fuji

Generated: June 25, 2018

DrugPatentWatch Database Preview

Claims for Patent: 7,662,787

« Back to Dashboard

Summary for Patent: 7,662,787
Title:Abuse resistant lysine amphetamine compounds
Abstract:The present invention describes compounds, compositions and methods of using the same comprising lysine covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Inventor(s): Mickle; Travis (Coralville, IA), Krishnan; Suma (Belvedere, CA), Bishop; Barney (Annandale, VA), Lauderback; Christopher (Blacksburg, VA), Moncrief; James Scott (Christiansburg, VA), Oberlender; Rob (Blacksburg, VA), Piccariello; Thomas (Blacksburg, VA), Paul; Bernhard J. (Slingerlands, NY), Verbicky; Christopher A. (Broadalbin, NY)
Assignee: Shire LLC (Florence, KY)
Application Number:11/745,019
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,662,787
Patent Claims: 1. A compound selected from the group consisting of isolated L-lysine-d-amphetamine and a pharmaceutically acceptable salt of L-lysine-d-amphetamine.

2. Isolated L-lysine-d-amphetamine.

3. L-lysine-d-amphetamine mesylate.

4. L-lysine-d-amphetamine hydrochloride.

5. A pharmaceutically acceptable salt of L-lysine-d-amphetamine.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
McKinsey
Boehringer Ingelheim
Deloitte
UBS
Dow
Cantor Fitzgerald
Chinese Patent Office
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.